Sign In
Skip Navigation Links.
Expand AboutAbout
Our People
Expand Quick LinksQuick Links
Expand MediaMedia
Advisory Board Committee
Prof.Maha M. Saber-Ayad Clinical Sciences Department Academic RankProfessor


  • Pharmacology

Research Interests:

  • Pharmacogenomics and Precision Medicine, Colorectal cancer research (therapeutic targets and prognostic markers)


"MBBCh, MSc, MD, MRCP(UK), FRCP(Edin.) MSc in Endocrinology and Diabetes, Queen Mary University, UK MSc in Leadership in Health Profession Education, RCSI, Ireland (joint with the UoS) "
"Jan 2022- present Professor of Pharmacology, College of Medicine, University of Sharjah June 2015-Jan 2022 Associate Professor of Pharmacology, College of Medicine, University of Sharjah, UAE March 2019 Promotion to Professor of Pharmacology, Faculty of Medicine, Cairo University, Egypt September 2016- August 2018 Chair of Basic Medical Sciences Department, College of Medicine, University of Sharjah 2013-2019 Associate Professor of Pharmacology, Faculty of Medicine, Cairo University, Egypt 2009- 2015 Assistant Professor of Pharmacology, College of Medicine, University of Sharjah, UAE 2004- 2010 Tutor in the Egyptian Medical Syndicate preparatory courses for MRCP(UK). 2008- 2009 Member of the Committee of Clinical Pharmacology & Pharmacy, Cairo University Hospitals. 2006- Jan, 2009 Clinical and genetic consultant of Bibliotheca Alexandrina Hypertrophic Cardiomyopathy (BA-HCM) research project in Cairo (the project is under support of Magdi Yacoub Research Institute in Harefield and Oxford University- UK). 2006-2013 Assistant Professor of Pharmacology, Faculty of Medicine, Cairo University, Egypt 2003-2004 Part-time Resident, Intermediate Care of Cardiology Department, New University Teaching Hospital, Cairo University. 2001-2006 Lecturer of Pharmacology, Faculty of Medicine, Cairo University, Egypt 1999-2001 Demonstrator of Pharmacology, Faculty of Medicine, Cairo University, Egypt 1997-1999 Full-time Resident, Critical Care Department, Kasr Al-Aini University Hospitals, Faculty of Medicine, Cairo University. 1996-1997 House Officer (Internship), Kasr Al-Aini University Hospitals, Faculty of Medicine, Cairo University. "
"1. Co-Chair of the “Promotion Committee”, College of Medicine, UoS 2. Member of the “Bio-informatics and Functional Genomics” UoS research group 3. Member of the “Environment and Cancer” UoS research group 4. Member of the Pharmacogenomics Global Research Network 5. Member of the Clinical Research Working Group of the EACPT: assessment of drug response variability 6. Collaborator of Global Burden of Disease "
"2. Fellow of the Royal College of Physician, Edinburgh, UK 3. Member of the British Pharmacology Society 4. Member of European Association for Clinical Pharmacology and Therapeutics (EACPT) 5. Member of the of the human population clinical research working group of (EACPT). 6. Member of European Association for Cancer Research (EACR) 7. Member of Pharmacogenomics Research Network 8. Member of the Clinical Pharmacogenomics Implementation Consortium (CPIC) 9. Member of the Emirates Medical Association 10. Global Burden of Disease Collaborator (“GBD” Collaborator) 11. Member of the editorial board of: Experimental and Therapeutic Medicine 12. Member of the Editorial Board: Advances in Biomedical and Health Sciences 13. Associate Editor: Beni-Suef University Journal of Basic and Applied Sciences 14. Review editor of the “Anti-cancer drug” section in Frontiers in Pharmacology and Frontiers in Oncology. 15. Reviewer in: 1. British Journal of Clinical Pharmacology 2. Journal on Complementary Medicine and Drug Discovery 3. Frontiers in Pharmacology 4. Frontiers in Oncology 5. Current Pharmaceutical Design 6. International Journal of Cancer 7. Clinical Genetics 8. Pharmacogenomics 9. BMC medical genomics 10. Pharmaceuticals 11. Pharmaceutics 12. Molecules 13. Genes and Nutrition 14. Journal of Renin-Angiotensin Aldosterone System 15. Cell Biochemistry and Biophysics 16. Clinical Medicine and Diagnostics 17. Journal of Mood Disorders 18. Asian Pacific Journal of Tropical Biomedicine 19. African Health Sciences 20. Lipids in Health and disease 21. PLOS ONE 22. Human Cell 23. Oncology Reports 24. Oncology Letters 25. Peer J 26. Advances in Biomedical and Health Sciences 27. Hamdan Medical Journal 28. Journal of Precision Medicine "
" 1. Exploring the Relevance of Pharmacogenetics Testing in Patients with Asthma, Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences (185000) 2. Combined inhibition of Insulin Growth Factor 1 Receptors and Autophagy to Prevent Colorectal Cancer Metastasis: A Novel Therapeutic Approach, MBRU-AlMahmeed Collaborative Research Award, 300000AED 3. Impact of Gene Variants on Therapeutic and Immune Response in COVID-19 patients: A predictive model of the Disease Outcome, UoS, 210000AED 4. Development of Emirati Pharmacogenomics Passport: towards practicing personalized medicine in UAE, UoS and University of Lübeck, 400000AED 5. Repurposing of Montelukast in treatment of early diabetic kidney disease, UoS, 80000AED 6. Exploring mechanisms of 5FU-resistance in colorectal cancer cells with deficient DNA mismatch repair, UoS, 200000AED 7. Role of Galanin/Galanin Receptor signaling as a potential novel therapeutic target for Colo-rectal Cancer with mutant p53, Al Jalila Foundation Seed grant, 293,000AED 8. Effect of GLP-1 agonist (exendin-4) on proliferation, invasion, migration and apoptosis in pheochromocytoma and colorectal cancer cells, UoS, 80000AED 9. Prevalence of statin-induced myopathy SLCO 1B1 gene polymorphism in Emirati population, UoS, 110000AED 10. Effect of Galanin expression on caspase 8 –mediated apoptosis and sensitivity to chemotherapy in colorectal cancer, Boehringer Ingelheim, 11000AED 11. Prevalence of FTO obesity gene polymorphisms in UAE population, Boehringer Ingelheim, 10000AED "
"1. Mahgoub E, Taneera J, Sulaiman N and Saber-Ayad M*. The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. Front. Med 2022, 9:959348. (IF: 5) 2. Ragab, A.E.; Al-Madboly, L.A.; Al-Ashmawy, G.M.; Saber-Ayad, M*.; Abo-Saif, M.A. Unravelling the In Vitro and In Vivo Anti-Helicobacter pylori Effect of Delphinidin-3-O-Glucoside Rich Extract from Pomegranate Exocarp: Enhancing Autophagy and Downregulating TNF-α and COX2. Antioxidants 2022, 11, 1752. (IF: 7.6) 3. Bornstein SR, Cozma D, Kamel M, Hamad M, Mohammad MG, Khan NA, Saber MM, Semreen MH, Steenblock C. Long-COVID, Metabolic and Endocrine Disease. Horm Metab Res. 2022 Aug;54(8):562-566. doi: 10.1055/a-1878-9307. (IF: 2.9) 4. Talaat IM, Elemam NM, Zaher S and Saber-Ayad M (2022) Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment. Front. Med. 9:955599. (IF: 5) 5. The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019, Khanh Bao et al. The Lancet 2022; 400: 563 – 591 (as a GBD 2019 Cancer Risk Factors Collaborator). (IF: 202.7) 6. Bajbouj K, Al Ali A, Shafarin J, Sahnoon L, Sawan A, Shehada A, Elkhalifa WE, Saber-Ayad M, Muhammad JS, Elmoselhi AB, Guraya SY and Hamad M. Vitamin D exerts significant anti-tumor effects by suppressing vasculogenic mimicry in breast cancer cells. Front. Oncol. 12:918340. (IF: 6.244). 7. Talaat IM, Yakout NM, Soliman ASA, Venkatachalam T, Vinod A, Eldohaji L, Nair V, Hareedy A, Kandil A, Abdel-Rahman WM, Hamoudi R and Saber-Ayad M* (2022) Evaluation of Galanin Expression in Colorectal Cancer: An Immunohistochemical and Transcriptomic Study. Front. Oncol. 2022;12:877147 (IF: 6.244). 8. Laham AJ, El-Awady R, Lebrun JJ, Saber-Ayad M*. A Bioinformatics Evaluation of the Role of Dual-Specificity Tyrosine-Regulated Kinases in Colorectal Cancer. Cancers. 2022 Apr 18;14(8). (IF: 6.6). 9. Bajbouj K, Qaisar R, Alshura MA, Ibrahim Z, Alebaji MB, Al Ani AW, Janajrah HM, Bilalaga MM, Omara AI, Abou Assaleh RS, Saber-Ayad M. Synergistic Anti-Angiogenic Effect of Combined VEGFR Kinase Inhibitors, Lenvatinib, and Regorafenib: A Therapeutic Potential for Breast Cancer. International Journal of Molecular Sciences. 2022;23(8). (IF:5.9) 10. Elemam NM, Hammoudeh S, Salameh L, Mahboub B, Alsafar H, Talaat IM, Habib P, Siddiqui M, Hassan KO, Al-Assaf OY, Taneera J, Sulaiman N, Hamoudi R, Maghazachi A, Hamid Q, Saber-Ayad M*. Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling. Frontiers in immunology. 2022 Apr 20;13:865845 (IF: 8.78). 11. Madkour Zaher, M. I., Malhab, L. J. B., Abdel-Rahman, W. M., Abdelrahim, D., Saber-Ayad, M. M.*, & Faris, M. E (2022). Ramadan diurnal intermittent fasting is associated with attenuated FTO gene expression in subjects with obesity: A prospective cohort study. Frontiers in Nutrition. 8:741811. (IF:6.5) 12. Talaat, I.M., Elemam N., Saber-Ayad, M* (2022). Complement System: An Immunotherapy target in Colorectal Cancer. Frontiers in Immunology, 13: 810993. (IF: 8.78) 13. GBD 2019 Diabetes Mortality Collaborators. Diabetes mortality and trends before 25 years of age: an analysis of the Global Burden of Disease Study 2019. Lancet Diabetes Endocrinol. 2022 10(3):177-192. (IF:32.069) 14. Mohammed, G., Mousa, N. A., Talaat, I. M., Ibrahim, H., & Saber-Ayad, M. (2021). Breast Cancer Risk with Progestin Subdermal Implants: A Challenge in Patients Counseling. Frontiers in Endocrinology, 12: 781066. (IF:5.5) 15. Manzoor, S., Saber-Ayad, M.*, Maghazachi, A. A., Hamid, Q., & Muhammad, J. S. (2022). MLH1 mediates cytoprotective nucleophagy to resist 5-Fluorouracil-induced cell death in colorectal carcinoma. Neoplasia, 24(2), 76-85. (IF:5.7) 16. Alvarez, E. M., Force, L. M., Xu, R., Compton, K., Lu, D., Henrikson, H. J., ... & Burkart, K. (2022). The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. The Lancet Oncology, 23(1), 27-52 (as a GBD collaborator). (IF: 41.3) 17. Bajbouj, K.; Al-Ali, A.; Ramakrishnan, R.K.; Saber-Ayad, M.*; Hamid, Q. Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets. Int. J. Mol. Sci. 2021, 22, 11701. (IF: 5.9) 18. Hafezi, S.; Saber-Ayad, M.*; Abdel-Rahman, W.M. Highlights on the Role of KRAS Mutations in Reshaping the Microenvironment of Pancreatic Adenocarcinoma. Int. J. Mol. Sci. 2021, 22, 10219. (IF: 5.9) 19. Saber-Ayad, M.*; Hammoudeh, S.; Abu-Gharbieh, E.; Hamoudi, R.; Tarazi, H.; Al-Tel, T.H.; Hamid, Q. Current Status of Baricitinib as a Repurposed Therapy for COVID-19. Pharmaceuticals 2021, 14, 680. (IF: 5.8) 20. El-Kady, M.M.; Naggar, R.A.; Guimei, M.; Talaat, I.M.; Shaker, O.G.; Saber-Ayad, M*. Early Renoprotective Effect of Ruxolitinib in a Rat Model of Diabetic Nephropathy. Pharmaceuticals 2021, 14, 608. (IF: 5.8) 21. Bajbouj, K.; Ramakrishnan, R.K.; Saber-Ayad, M.*; Omar, H.A.; Saheb Sharif-Askari, N.; Shafarin, J.; Elmoselhi, A.B.; Ihmaid, A.; AlHaj Ali, S.; Alalool, A.; Abdullah, R.; Hamid, Q. PRMT5 Selective Inhibitor Enhances Therapeutic Efficacy of Cisplatin in Lung Cancer Cells. Int. J. Mol. Sci. 2021, 22, 6131. (IF: 5.9) 22. Elaraby, E.; Malek, A.I.; Abdullah, H.W.; Elemam, N.M.; Saber-Ayad, M.; Talaat, I.M. Natural Killer Cell Dysfunction in Obese Patients with Breast Cancer: A Review of a Triad and Its Implications. J Imm Res 2021, 2021, 9972927. (IF: 4.8) 23. Naja, F.; Itani, L.; Hammoudeh, S.; Manzoor, S.; Abbas, N.; Radwan, H.; Saber-Ayad, M*. Dietary Patterns and Their Associations With the FTO and FGF21 Gene Variants Among Emirati Adults. Frontiers in Nutrition 2021, 8, 211, doi:10.3389/fnut.2021.668901. (IF: 6.5) 24. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25):2982-3021 (as a GBD collaborator). (IF: 24.09) 25. Laham, A. J., Saber-Ayad, M.* & El-Awady, R. DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis. Cellular and Molecular Life Sciences 2021, 78(2):603-619. (IF: 9.2) 26. Saber-Ayad M*, Hammoudeh S, Radwan H, Manzoor S, Jabbar H, Wardeh R, Ashraf A, Habib P, Alsamman AM, Hamoudi R. The FGF-21 Genetic Variants rs838133 and rs838145 are Associated with High Salt Intake in the Emirati Population. Journal of Advanced Research, 2020, 24: 485-494. (IF: 10.4) 27. Saber-Ayad M*, Saleh MA, Abu-Gharbieh E. The Rationale for Potential Pharmacotherapy of COVID-19. Pharmaceuticals 2020, 13, 96. (IF: 5.8) 28. Elsharkawi I, Divyasree P, Saber-Ayad M, Khan A, El-Serafi A. Exploring the effect of epigenetic modifiers on developing insulin-secreting cells. Human Cell 2019, 33(1): 1-9. (IF: 4.17) 29. Saber-Ayad M*, Manzoor S, Radwan H, Hammoudeh S,Wardeh R, Ashraf A, Jabbar H, Hamoudi R. The FTO genetic variants are associated with dietary intake and body mass index amongst Emirati population. PLoS ONE 2019,14(10). (IF: 3.2) 30. Saber-Ayad M*, Manzoor S, El-Serafi A, Mahmoud I, Hammoudeh S, Rani A, Abusnana S, Sulaiman N. The FTO rs9939609 “A” allele is associated with impaired fasting glucose and insulin resistance in Emirati population. Gene 2019; 681:93-98. (IF: 3.6) 31. Saber-Ayad M*, Manzoor S, El-Serafi A, Mahmoud I, Abusnana S, Sulaiman N. Statin-induced myopathy SLCO1B1 521T>C is associated with Prediabetes, high Body mass index and normal lipid profile in Emirati Population. Diabetes Res Clin Pract 2018; 139: 272-277. (IF: 5.6) 32. Abdel-Rahman W., Al-khayyal N, Nair V, Aravind SR, Saber-Ayad M. Role of AXL in invasion and drug resistance of colon and breast cancer cells and its association with p53 alterations. World J Gastroenterol 2017; 23(19): 3440-3448. (IF: 5.7) 33. El-Awady R, Semreen MH, Saber-Ayad M, Cyprian F, Menon V, Al-Tel T. Modulation of DNA damage response and induction of apoptosis mediates synergism between doxorubicin and a new imidazopyridine derivative in breast and lung cancer cells. DNA Repair 2016;37: 1-11. (IF: 4.9) 34. Semreen MH, EL-Awady R, Abu-Odeh R, Saber-Ayad M, Al-Qawasmeh R, Chouaib S, Voelter W, Al-Tel T. Tandem Multicomponent Reactions toward the design and synthesis of novel antibacterial and cytotoxic motifs. Curr Med Chemistry 2013;20: 1445-59. (IF: 4.1) 35. Johnson JN, Grifoni C, Bos JM, Saber-Ayad M, Ommen SR, Nistri S, Cecchi F, Olivotto I, Ackerman MJ. Prevalence and clinical correlates of QT prolongation in patients with hypertrophic cardiomyopathy. Eur Heart J. 2011 May;32(9):1114-20. (IF: 29.9) "
"a. Exploring the Effect of Autophagy Inhibition on the Colorectal Cancer Response to Immunotherapy, (PhD project of Ms Nasrah Alkhemeiri) - ongoing project. b. The role of “TIGAR” in Colorectal Cancer Cells with different Autophagy and Mismatch-repair Status: Effect on Proliferation, Migration and Drug Resistance, (MSc project of Ms Fatima Abdalla Almaazmi)- ongoing project. c. Pharmacogenomics in the cardiology and gastro-enterology clinics in the UAE, (MSc project of Ms Qamar Osamah)- ongoing project. d. The role of Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) in DNA repair and response of cancer cells to chemotherapy (PhD project co-supervisor of Ms Amina Laham; the main supervisor is Prof. Raafat Al Awady)- ongoing project. e. Exploring the role of pharmacogenomics in psychiatric medications in Emirati Patients. MSc thesis of Ms Aminah Al Chakee (2022-2023). f. Effect of glucagon-like peptide-1 receptor agonist exendin-4 on proliferation of Breast cancer cells (MSc project – main supervisor of Ms Fatema Omar). g. Role of ABCB1 Gene polymorphism on cyclosporine blood concentration in renal transplanted patients (PhD project co-supervisor of Mr Gomaa Hedeab; the main supervisor is Prof. Magda Zaki, Cairo University). h. Effect of Angiotensin-Converting Enzyme (ACE) I/D Gene Polymorphism on Steroid Resistance in Egyptian Children with Idiopathic Nephrotic Syndrome, (MSc project- main supervisor of Ms Hanaa Nabil)- (Cairo University). "
First place oral presentation in the 10th Emirates Diabetes and Endocrinology Congress (EDEC), as a supervisor of the project “The FTO genetic variants are associated with dietary intake and body mass index amongst Emirati population”, February, 2020.
"1. Participating in the “Transformative Leadership in Health Profession Education” conducted by the TUHF Academy (attached certificate). TUFH stands for “Towards Unity for Health”. 2. Facilitating Action learning sets (ALS) for the EmPower program of Johnson & Johnson for “Women in Leadership” in collaboration with the Royal College of Surgeons in Ireland. The program aims to train women and develop their skills to lead changes in their organizations 3. Writing Effective Research Proposals. Women in research seminar series, University of Sharjah, Dec 2020. 4. How to write a research proposal? How to do Clinical Research?”. (Webinar), College of Medicine, University of Sharjah, Dec 2020. 5. Drugs and Acute Kidney Injury: A clinical approach (2nd Acute Kidney Injury Symposium, 2021 – online oral presentation and workshop) 6. Personalized Medicine seminar for Innovation@UAE (UAE Ministry of Education), October, 2021 (oral presentation and interactive session). 7. How the genes affect your medicines and diet (in Arabic) for the Health promotion department in collaboration with the University of Sharjah, Dec 2021. 8. The current status of Immunomodulators in the treatment of COVID-19. DUPHAT, Feb 2022 (oral presentation). 9. Pharmacogenomics: from the Lab to the Clinic, College of Medicine, University of Sharjah, Mar 2022 (oral presentation). "
"I consider teaching one of the most interesting and enjoyable tasks I do. I’ve been involved in teaching since 1999. My ultimate goal is to help student acquire the passion for learning. They should get the knowledge, skills and attitude that enable them to satisfy the patient needs. With the rapidly evolving knowledge in every and each specialty and branch of science, students should have enough curiosity to become life-long learners. For a successful learning process, we should build on what the students know through stimulating questions. My main task in all courses is to foster critical thinking and clinical reasoning regarding therapeutics, and to encourage involvement of the students in fruitful discussion. Problem solving is usually more interesting for the students and more close to real life, and represents what is expected in their practice in the future. It is a part of authentic learning. I try to focus on discussing basic as well as practical issues in depth, rather than flooding them with unnecessary peripheral information; quality of information is much more important. Developing a good relationship between patients and health care team is one of the major goals I am trying to emphasize all through my courses for future physicians, pharmacists and dentists, whom I taught over the years. Being knowledgeable and mastering communication skills provide the students with the confident attitude required in their practice. I teach both small and large groups of students. In small PBL groups, it is easier to promote one-to-one discussions as well as group discussion. In large groups, it is difficult unless we use approaches like TBL. I find TBL sessions very useful for students. "
Back to list